NASHVILLE, Tenn. , Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.
(Nasdaq: CPIX ), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes on Thursday, Nov. 7, 2024 . A conference call will be held on Nov.
7 at 4:30 p.m. Eastern Time to discuss the results.
To participate in the call, please register at https://register.vevent.com/register/BIdd190691b1df432e9f1f65383f53b384 .
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference. A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting https://edge.
media-server.com/mmc/p/cm7m7ea3 . Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care.
The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote ® ( acetylcysteine ) injection, for the treatment of acetaminophen poisoning; Caldolor ® ( ibuprofen ) injection, for the treatment of pain and fever; Kristalose ® ( lactulose ) for oral solution, a prescription laxative, for the treatment of constipation.
